Proteins

Product Data Sheet

AZD8309

Cat. No.: HY-119259 CAS No.: 333742-48-6 Molecular Formula: $C_{15}H_{14}F_{2}N_{4}O_{2}S_{2}$

Molecular Weight: 384.42 CXCR Target:

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage: 4°C, sealed storage, away from moisture and light

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (130.07 mM; Need ultrasonic)

| | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|---------------------------|-------------------------------|-----------|------------|------------|
| Preparing Stock Solutions | 1 mM | 2.6013 mL | 13.0066 mL | 26.0132 mL |
| | 5 mM | 0.5203 mL | 2.6013 mL | 5.2026 mL |
| | 10 mM | 0.2601 mL | 1.3007 mL | 2.6013 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description AZD8309 is an orally active antagonist of CXCR2. AZD8309 has the ability to regulate the transmigration of neutrophils.

AZD8309 can be used in the study of inflammatory diseases[1].

IC₅₀ & Target CXCR2

4 nM (IC₅₀)

In Vivo AZD8309 (50 mg/kg; p.o.; twice daily) reduces neutrophil migration and pancreatic protease activation in experimental pancreatitis in mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| Animal Model: | Male C57BL6 mice (25-30 g) with experimental pancreatitis ^[1] |
|-----------------|--|
| Dosage: | 50 mg/kg |
| Administration: | Oral gavage; twice daily starting 3 h prior to pancreatitis induction |

| Result: | Significantly reduced MPO in the pancreas and lungs (8 h & 24 h) and reduce |
|---------|--|
| | intrapancreatic trypsin and elastase activity (8 h) in caerulein-pancreatitis. |
| | Reduced serum cytokine levels as well as histopathological damage. |

REFERENCES

- [1]. Malla SR, et al. Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis. Pancreatology. 2016 Sep-Oct;16(5):761-9.
- [2]. Walters I, Austin C, Austin R, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett. 2008;18(2):798-803.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-ma

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com